The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it, and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take lecanemab (Leqembi) due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Ambar Kulshreshtha, MD, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but lecanemab clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
The drug also can cause brain swelling and bleeding. Patients need regular brain scans to monitor for that.
The FDA gave lecanemab full approval last summer for patients with early stages of the disease. The federal Medicare program for people ages 65 and over covers lecanemab and the cost of scans needed to diagnose patients.
The drug’s maker, Japan’s Eisai, initially expected to have 10,000 patients taking the IV drug by the end of March. Company executives have since backed off that projection, though they say sales are growing.
Hospitals and health systems have needed more time than expected to set up their systems for delivering lecanemab, said Alexander Scott, an Eisai executive vice president.
“It’s not like we are adding a drug to an existing system,” he said. “They are building the system for the drug.”
The Cedars-Sinai health system in Los Angeles started administering the drug in early March. Getting there required months of meetings to iron out a plan to coordinate diagnosis, treatment, and then monitoring for problems.
“We were very careful about it,” said Sarah Kremen, MD, a behavioral neurologist.
Banner Health in Arizona also recently started using lecanemab at a couple specialty clinics in Phoenix, a spokeswoman said.
“This is a very phased and staged approach,” said Alireza Atri, MD, PhD, a neurologist who has worked as a paid consultant for Eisai. “As we learn more, we’ll expand and extend it.”
The Mayo Clinic in Rochester, Minnesota, started using lecanemab in October but only for patients who live within a 100-mile radius so it can reach them quickly if they develop side effect symptoms. Doctors evaluate three to five patients every week for potential treatment, said Alzheimer’s expert Ron Petersen, MD, PhD.
Health systems are still trying to understand how coverage for the drug, its infusions, and the needed scans works so patients don’t get stuck with bills. That’s a significant variable for a drug that can cost more than $26,000 a year.
An Eisai spokeswoman said nearly three-quarters of commercial plans in the U.S. cover the drug outside Medicare.
But doctors are concerned that coverage still may be tough for some patients, especially those too young to qualify for Medicare.
Insurance denials delayed Scott Berkheiser’s first lecanemab infusion a few months until last December. The 57-year-old Venice, Florida, resident said the drugmaker eventually agreed to give it to him for free while he makes co-payments for the infusions.
“It was a little crazy,” he said. “It seemed like it was kind of a game that must make sense for some monetary reason.”
Getting treatments started on time remains another challenge.
Texas Neurology had 60 patients screened as possible candidates for lecanemab and on a waitlist when the drug launched last year. Only eight eventually started treatment. The rest either declined to take it or had advanced beyond the mild phase of the disease when they were rescreened, CEO David Evans said.
“That window gets very short very quick,” he said.
Doctors say more must be done to quickly identify patients and get treatment started before the disease advances. But that’s a murky process.
If people mention memory trouble, doctors must rule out reversible causes like thyroid problems, vitamin deficiencies, medication issues, or depression, Kulshreshtha said. Then memory tests for dementia can take a few visits.
Some patients may be ineligible for lecanemab because it would conflict with medication they already take to prevent strokes.
And then getting in to see a neurologist who prescribes the drug can take months.
Those who make it to the first infusion say the treatment process is manageable. Berkheiser says infusions have gone “like clockwork” since his delayed start.
He fits them in between his work as an engineer and training 6 days a week to compete in an Ironman triathlon.
Charles “Bum” Clegg recently finished his 13th lecanemab infusion. The Salem, Alabama, resident visits a treatment center only 15 minutes from his home.
Clegg and his wife, Carol, say he has had no side effects, and his short-term memory has improved.
“This drug gives you hope,” Carol said.
Treatment access may improve over time. The FDA is reviewing another potential treatment that targets amyloid protein, Eli Lilly’s donanemab. Eisai is planning to seek approval for an injectable version of lecanemab that would be easier to use. Blood tests may eventually speed up amyloid detection.
But researchers say there’s still a long road ahead. It’s not clear what causes Alzheimer’s disease, and many think combination treatments will be needed to stop it.
“We still have a lot to learn about Alzheimer’s,” said Eric Widera, MD, a geriatric specialist with the University of California San Francisco. “It’s complex, and it’s much more than amyloid.”
Please enable JavaScript to view the